These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20346005)

  • 21. Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients.
    Govil A; Walsh RC; Tevar A; Alloway R; Roy-Chaudhury P; Mogilishetty G; Wall GE; Brailey P; Girnita A; Woodle ES
    Clin Transpl; 2009; ():443-53. PubMed ID: 20524313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib-associated cutaneous vasculitis.
    Garcia-Navarro X; Puig L; Fernández-Figueras MT; Dalmau J; Roe E; Alomar A
    Br J Dermatol; 2007 Oct; 157(4):799-801. PubMed ID: 17635511
    [No Abstract]   [Full Text] [Related]  

  • 23. The role of bortezomib in the treatment of lymphoma.
    Barr P; Fisher R; Friedberg J
    Cancer Invest; 2007 Dec; 25(8):766-75. PubMed ID: 18058474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection.
    Al Meshari K
    Clin Transpl; 2009; ():385-6. PubMed ID: 20524302
    [No Abstract]   [Full Text] [Related]  

  • 25. [Proteasome inhibitors--new option in the treatment of tumor diseases].
    Spicka I; Klener P
    Cas Lek Cesk; 2004; 143(10):701-4. PubMed ID: 15584622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
    Jagannath S; Barlogie B; Berenson JR; Singhal S; Alexanian R; Srkalovic G; Orlowski RZ; Richardson PG; Anderson J; Nix D; Esseltine DL; Anderson KC;
    Cancer; 2005 Mar; 103(6):1195-200. PubMed ID: 15690325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line?
    Lee I; Constantinescu S; Gillespie A; Swami A; Birkenbach M; Leech S; Silva P; Karachristos A; Daller JA; Sifontis NM
    Clin Transpl; 2009; ():425-9. PubMed ID: 20524309
    [No Abstract]   [Full Text] [Related]  

  • 28. Proteasome inhibitor holds promise for patients with refractory multiple myeloma.
    Expert Rev Anticancer Ther; 2001 Dec; 1(4):509-10. PubMed ID: 12113081
    [No Abstract]   [Full Text] [Related]  

  • 29. Proteasome inhibition for treatment of multiple myeloma: clinical update.
    Stadtmauer EA
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteasome inhibitors in pediatric cancer treatment.
    Bachmann AS
    Hawaii Med J; 2008 Sep; 67(9):247-9. PubMed ID: 18853901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
    Dimopoulos MA; Anagnostopoulos A; Kyrtsonis MC; Castritis E; Bitsaktsis A; Pangalis GA
    Haematologica; 2005 Dec; 90(12):1655-8. PubMed ID: 16330439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful desensitization in a crossmatch positive living-related kidney transplant recipient using a bortezomib-based protocol.
    Zhu L; Lin Z; Xiang Y; Liu S; Chen G
    Clin Transpl; 2009; ():359-60. PubMed ID: 20524298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis.
    Kelley TW; Alkan S; Srkalovic G; Hsi ED
    Leuk Res; 2004 Aug; 28(8):845-50. PubMed ID: 15203282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New treatment approaches in multiple myeloma.
    Berrebi A
    Isr Med Assoc J; 2005 Dec; 7(12):820-1. PubMed ID: 16382710
    [No Abstract]   [Full Text] [Related]  

  • 35. [Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].
    Takatoku M; Noborio-Hatano K; Takahashi S; Kikuchi S; Mori M; Muroi K; Komatsu N; Ozawa K
    Rinsho Ketsueki; 2004 Feb; 45(2):144-8. PubMed ID: 15045823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular profiles of proteasome inhibition in plasma cell dyscrasias.
    Mitsiades CS
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S23-7. PubMed ID: 19795532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bortezomib alone fails to decrease donor specific anti-HLA antibodies: 4 case reports.
    Sberro-Soussan R; Zuber J; Suberbielle-Boissel C; Legendre C
    Clin Transpl; 2009; ():433-8. PubMed ID: 20524311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review.
    Besada E; Vik A; Koldingsnes W; Nossent JC
    Int J Hematol; 2013 Jun; 97(6):800-3. PubMed ID: 23616220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Faderl S; Rai K; Gribben J; Byrd JC; Flinn IW; O'Brien S; Sheng S; Esseltine DL; Keating MJ
    Cancer; 2006 Sep; 107(5):916-24. PubMed ID: 16832816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proteasome inhibitors in non-Hodgkin's lymphoma.
    Zelenetz A
    J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S34-6. PubMed ID: 16280110
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.